2. Anti-infection
  3. Fungal SARS-CoV HIV
  4. Pradimicin A

Pradimicin A (PRM-A) 是一种有效的抗真菌剂，对褶假丝酵母的最低抑制浓度 (MIC )为 4 μg/mL。Pradimicin A 对SARS-CoV 病毒，人类免疫缺陷病毒 (HIV) 和其他包膜病毒具有抗病毒活性。Pradimicin A 具有聚集性，在 Ca2+ 离子存在时能够识别 d-Man。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Pradimicin A Chemical Structure

Pradimicin A Chemical Structure

CAS No. : 117704-65-1

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

Pradimicin A 相关抗体

Top Publications Citing Use of Products

查看 HIV 亚型特异性产品:

查看所有亚型
HIV HIV-1 HIV-2

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Pradimicin A (PRM-A) is a potent antifungal agent, with an MIC of 4 μg/mL against Candida rugosa. Pradimicin A has antiviral activities against CoV, HIV and other enveloped viruses. Pradimicin A shows aggregation property, and can recognize d-Man in the presence of Ca2+ ion[1][2].

IC50 & Target

MIC: 4 μg/mL (Candida rugosa)[1]
细胞效力
(Cellular Effect)
Cell Line Type Value Description References
C8166 CC50
> 50 μM
Compound: PRM-A
Cytotoxicity against human C8166 cells after 3 to 4 days
Cytotoxicity against human C8166 cells after 3 to 4 days
[PMID: 20047920]
C8166 EC50
2.6 μM
Compound: PRM-A
Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by microscopic analysis
Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by microscopic analysis
[PMID: 20047920]
Caco-2 CC50
> 50 μM
Compound: PRM-A
Cytotoxicity against human Caco2 cells after 3 to 4 days
Cytotoxicity against human Caco2 cells after 3 to 4 days
[PMID: 20047920]
CCRF-CEM CC50
> 100 μM
Compound: PRM-A
Cytotoxicity against human CEM cells after 7 days by trypan blue staining
Cytotoxicity against human CEM cells after 7 days by trypan blue staining
[PMID: 20047920]
CCRF-CEM CC50
> 100 μM
Compound: Pradimicin A
Cytotoxicity against human CEM cells assessed as cell count after 3 days
Cytotoxicity against human CEM cells assessed as cell count after 3 days
[PMID: 26513643]
CCRF-CEM EC50
> 50 μM
Compound: PRM-A
Cytotoxicity against human CEM cells after 4 days by by Coulter counter analysis
Cytotoxicity against human CEM cells after 4 days by by Coulter counter analysis
[PMID: 21749165]
CCRF-CEM EC50
> 50 μM
Compound: PRM-A
Antiviral activity against HIV-1 3B harboring wild type gp120 infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by microscopic analysis
Antiviral activity against HIV-1 3B harboring wild type gp120 infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by microscopic analysis
[PMID: 20047920]
CCRF-CEM EC50
3.3 μM
Compound: Pradimicin A
Antiviral activity against HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 to 5 days by microscopic analysis
Antiviral activity against HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 to 5 days by microscopic analysis
[PMID: 26513643]
CCRF-CEM EC50
3.3 μM
Compound: Pradimicin
Antiviral activity against HIV1 3B infected in human CEM cells assessed as reduction in virus-induced cytopathicity after 4 to 5 days by microscopy based syncytium cell formation assay
Antiviral activity against HIV1 3B infected in human CEM cells assessed as reduction in virus-induced cytopathicity after 4 to 5 days by microscopy based syncytium cell formation assay
[PMID: 25617695]
CCRF-CEM EC50
3.4 μM
Compound: PRM-A
Antiviral activity against HIV1 3B infected in human CD4+ T-lymphocyte CEM cells assessed as inhibition of virus-induced cytopathicity after 4 to 5 days by microscopic analysis
Antiviral activity against HIV1 3B infected in human CD4+ T-lymphocyte CEM cells assessed as inhibition of virus-induced cytopathicity after 4 to 5 days by microscopic analysis
[PMID: 26540494]
CCRF-CEM EC50
4.3 μM
Compound: PRM-A
Antiviral activity against SIV mac251 infected in human HUT78 cells assessed as prevention of syncytium formation between persistently SIV mac251-infected HUT-78 cells and uninfected CEM cells after 3 to 4 days by ELISA
Antiviral activity against SIV mac251 infected in human HUT78 cells assessed as prevention of syncytium formation between persistently SIV mac251-infected HUT-78 cells and uninfected CEM cells after 3 to 4 days by ELISA
[PMID: 20047920]
CCRF-CEM EC50
5.2 μM
Compound: PRM-A
Antiviral activity against HIV-2 ROD infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by microscopic analysis
Antiviral activity against HIV-2 ROD infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by microscopic analysis
[PMID: 20047920]
CCRF-CEM EC50
5.2 μM
Compound: PRM-A
Antiviral activity against compound pretreated HIV-1 3B isolate 42 harboring gp120 mutant infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by microscopic analysis
Antiviral activity against compound pretreated HIV-1 3B isolate 42 harboring gp120 mutant infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by microscopic analysis
[PMID: 20047920]
CCRF-CEM EC50
5.2 μM
Compound: PRM-A
Antiviral activity against HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days
Antiviral activity against HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days
[PMID: 21749165]
CCRF-CEM EC50
5.9 μM
Compound: PRM-A
Antiviral activity against HIV-1 3B infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by microscopic analysis
Antiviral activity against HIV-1 3B infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by microscopic analysis
[PMID: 20047920]
CCRF-CEM EC50
5.9 μM
Compound: PRM-A
Antiviral activity against HIV2 ROD infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days
Antiviral activity against HIV2 ROD infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days
[PMID: 21749165]
CCRF-CEM EC50
5.9 μM
Compound: Pradimicin A
Antiviral activity against HIV2 ROD infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 to 5 days by microscopic analysis
Antiviral activity against HIV2 ROD infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 to 5 days by microscopic analysis
[PMID: 26513643]
CCRF-CEM EC50
5.9 μM
Compound: Pradimicin
Antiviral activity against HIV2 ROD infected in human CEM cells assessed as reduction in virus-induced cytopathicity after 4 to 5 days by microscopy based syncytium cell formation assay
Antiviral activity against HIV2 ROD infected in human CEM cells assessed as reduction in virus-induced cytopathicity after 4 to 5 days by microscopy based syncytium cell formation assay
[PMID: 25617695]
HeLa CC50
> 50 μM
Compound: PRM-A
Cytotoxicity against human HeLa cells after 3 to 4 days
Cytotoxicity against human HeLa cells after 3 to 4 days
[PMID: 20047920]
L1210 CC50
> 50 μM
Compound: PRM-A
Cytotoxicity against mouse L1210 cells after 3 to 4 days
Cytotoxicity against mouse L1210 cells after 3 to 4 days
[PMID: 20047920]
MOLT-4 CC50
> 50 μM
Compound: PRM-A
Cytotoxicity against human Molt4 cells after 3 to 4 days
Cytotoxicity against human Molt4 cells after 3 to 4 days
[PMID: 20047920]
MT4 CC50
> 100 μM
Compound: PRM-A
Cytotoxicity against human MT4 cells assessed as cell viability measured after 5 days by MTS assay
Cytotoxicity against human MT4 cells assessed as cell viability measured after 5 days by MTS assay
[PMID: 35512567]
MT4 CC50
> 100 μM
Compound: PRM-A
Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTS/PES assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTS/PES assay
[PMID: 34229438]
MT4 CC50
> 100 μM
Compound: PRM-A
Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTS/PES assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTS/PES assay
[PMID: 31809045]
MT4 CC50
> 50 μM
Compound: PRM-A
Cytotoxicity against human MT4 cells after 7 days by trypan blue staining
Cytotoxicity against human MT4 cells after 7 days by trypan blue staining
[PMID: 20047920]
MT4 EC50
5 μM
Compound: PRM-A
Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 7 days by trypan blue staining
Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 7 days by trypan blue staining
[PMID: 20047920]
MT4 EC50
5.2 μM
Compound: PRM-A
Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 7 days by trypan blue staining
Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 7 days by trypan blue staining
[PMID: 20047920]
MT4 EC50
5.5 μM
Compound: PRM-A
Antiviral activity against SIV mac251 infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 7 days by trypan blue staining
Antiviral activity against SIV mac251 infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 7 days by trypan blue staining
[PMID: 20047920]
OST CC50
> 50 μM
Compound: PRM-A
Cytotoxicity against human thymidine kinase-negative OST cells after 3 to 4 days
Cytotoxicity against human thymidine kinase-negative OST cells after 3 to 4 days
[PMID: 20047920]
PBMC CC50
> 250 μM
Compound: PRM-A
Cytotoxicity against human PBMC after 7 days by trypan blue staining
Cytotoxicity against human PBMC after 7 days by trypan blue staining
[PMID: 20047920]
PBMC EC50
> 50 μM
Compound: PRM-A
Antiviral activity against HIV-1 3B cells infected in human PBMC cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by microscopic analysis
Antiviral activity against HIV-1 3B cells infected in human PBMC cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by microscopic analysis
[PMID: 20047920]
PBMC CC50
> 50 μM
Compound: PRM-A
Cytotoxicity against human PBMC cells after 3 to 4 days
Cytotoxicity against human PBMC cells after 3 to 4 days
[PMID: 20047920]
Raji IC50
16 μM
Compound: PRM-A
Antiviral activity against SIV mac251 infected in human Raji cells expressing DC-SIGN gene assessed as inhibition of virus capture by Raji cells after 60 mins by ELISA
Antiviral activity against SIV mac251 infected in human Raji cells expressing DC-SIGN gene assessed as inhibition of virus capture by Raji cells after 60 mins by ELISA
[PMID: 20047920]
Raji IC50
16 μM
Compound: PRM-A
Antiviral activity against SIV mac251 infected in human Raji cells expressing DC-SIGN gene assessed as prevention of syncytium formation between persistently HIV-1 3B-infected Raji cells and uninfected human C8166 cells after 60 mins by ELISA
Antiviral activity against SIV mac251 infected in human Raji cells expressing DC-SIGN gene assessed as prevention of syncytium formation between persistently HIV-1 3B-infected Raji cells and uninfected human C8166 cells after 60 mins by ELISA
[PMID: 20047920]
Raji IC50
21 μM
Compound: PRM-A
Antiviral activity against R5 tropic HIV-1 Bal infected in human Raji cells expressing DC-SIGN gene assessed as inhibition of virus capture by Raji cells after 60 mins by ELISA
Antiviral activity against R5 tropic HIV-1 Bal infected in human Raji cells expressing DC-SIGN gene assessed as inhibition of virus capture by Raji cells after 60 mins by ELISA
[PMID: 20047920]
Raji EC50
3.4 μM
Compound: PRM-A
Antiviral activity against compound pretreated X4 tropic HIV-1 3B infected in human Raji cells expressing DC-SIGN gene assessed as prevention of syncytium formation between persistently HIV-1 3B-infected Raji cells and uninfected human C8166 cells after 4
Antiviral activity against compound pretreated X4 tropic HIV-1 3B infected in human Raji cells expressing DC-SIGN gene assessed as prevention of syncytium formation between persistently HIV-1 3B-infected Raji cells and uninfected human C8166 cells after 4
[PMID: 20047920]
Raji IC50
3.5 μM
Compound: PRM-A
Antiviral activity against X4 tropic HIV-1 3B infected in human Raji cells expressing DC-SIGN gene assessed as inhibition of virus capture by Raji cells after 60 mins by ELISA
Antiviral activity against X4 tropic HIV-1 3B infected in human Raji cells expressing DC-SIGN gene assessed as inhibition of virus capture by Raji cells after 60 mins by ELISA
[PMID: 20047920]
Raji EC50
5.4 μM
Compound: PRM-A
Antiviral activity against X4 tropic HIV-1 3B infected in human Raji cells expressing DC-SIGN gene assessed as prevention of syncytium formation between persistently HIV-1 3B-infected Raji cells and uninfected human C8166 cells after 36 to 42 hrs by micro
Antiviral activity against X4 tropic HIV-1 3B infected in human Raji cells expressing DC-SIGN gene assessed as prevention of syncytium formation between persistently HIV-1 3B-infected Raji cells and uninfected human C8166 cells after 36 to 42 hrs by micro
[PMID: 20047920]
SUP-T1 EC50
3.4 μM
Compound: PRM-A
Antiviral activity against HIV-1 3B infected in human HUT78 cells assessed as prevention of syncytium formation between persistently HIV-1 3B-infected HUT-78 cells and uninfected SupT1 cells after 3 to 4 days by ELISA
Antiviral activity against HIV-1 3B infected in human HUT78 cells assessed as prevention of syncytium formation between persistently HIV-1 3B-infected HUT-78 cells and uninfected SupT1 cells after 3 to 4 days by ELISA
[PMID: 20047920]
U-87MG ATCC CC50
> 50 μM
Compound: PRM-A
Cytotoxicity against human U87 cells after 3 to 4 days
Cytotoxicity against human U87 cells after 3 to 4 days
[PMID: 20047920]
分子量

840.78

Formula

C40H44N2O18
CAS 号
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
参考文献

Pradimicin A 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Pradimicin A117704-65-1FungalSARS-CoVHIVSARS coronavirusHuman immunodeficiency virusAntifungal activityCandida rugosaCoVHuman immunodeficiency virus (HIV)Aggregation propertyAntiviral activityInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
Pradimicin A
目录号：
HY-132191
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z